What is the purpose of Emfib Gefitinib 250mg Tablet?
In people with certain types of malignancies, Emfib Gefitinib 250mg Tablet is used to treat non-small cell lung cancer that has progressed to other regions of the body. Gefitinib belongs to the kinase inhibitor class of drugs.
When should I take 250 mg of gefitinib?
Gefitinib should be taken once a day, with or without meals, as advised by your doctor. Place the tablet in a glass of water (4 to 8 ounces/120 to 240 milliliters) if you have problems swallowing it. 15 minutes of vigorous stirring. Immediately consume the entire combination.
Is gefitinib capable of curing lung cancer?
TKIs like gefitinib are extremely effective for non-small cell lung cancer (NSCLC) by activating EGFR mutations. However, no cured case of advanced NSCLC has been documented yet. The first case of EGFR-mutated lung cancer treated with gefitinib is presented here.
What are the Emfib Gefitinib 250mg Tablet side effects?
- Tenderness or pain in the abdomen or stomach.
- Stools made of clay
- appetite reduction
- severe diarrhea
- Skin rash or itching
- vomiting and nausea.
- Inflammation of the foot or lower legs
- Yellow skin or eyes
For more details Click Here.
How long can Emfib Gefitinib 250mg Tablet be taken?
Chemotherapy is a very normal regimen of infusions every three weeks for four cycles—of 12 weeks of treatment—and gefitinib is a daily medication that they take for two years.
Does Gefitinib 250mg make you scratch?
In patients on EGFR inhibitors, dry skin is very prevalent; vaginal dryness and itching, perineal dryness, and blepharitis have all been described.
Is Emfib Gefitinib 250mg Tablet carcinogenic?
Because many cytotoxic drugs cause apoptosis, gefitinib could be able to enhance their effects by lowering survival cues.
Is Gefitinib 250mg considered a prodrug?
Gemcitabine is a cytidine analog in which the hydroxyl on the ribose is replaced by two fluorine atoms. Gemcitabine is a prodrug that is converted into active metabolites that stop tumor development and promote apoptosis in malignant cells by substituting the building blocks of nucleic acids during DNA elongation.
What is the efficacy of gemcitabine?
For patients with unresectable locally advanced or metastatic pancreatic cancer, gemcitabine therapy has been the conventional first-line treatment since 1997. The 5-year survival rate for patients with metastatic disease is only 2%, while 1-year survival rates of 17 to 23% have been recorded with gemcitabine.